Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Exploration of targeting GPR56 and its cancer cell ligand as a novel immune checkpoint inhibition strategy

Project description

Immune checkpoint inhibitors strategy for cancer therapy

Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy by blocking immunosuppressive receptors and their ligands, thereby lifting immune suppression and enhancing antitumour T-cell activity. Identifying new immune checkpoints and expanding the range of cancer therapies are critical steps in overcoming therapeutic resistance and advancing cancer treatment. In collaboration with InProTher, researchers have discovered a novel immune checkpoint receptor-ligand pair involving a GPCR and a viral protein. The ERC-funded GPR-ICI project will focus on targeting GPCRs for therapeutic use. It will investigate how blocking the interaction between immune cells expressing the adhesion GPCR and cancer cells expressing the viral protein can serve as a new strategy for cancer therapy and ICIs.

Objective

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy over the last decade. In essence, ICIs block the interaction of immunosuppressive receptors and their ligands, which attenuate T cell activity and the secretion of pro-inflammatory cytokines. Blocking these inhibitory signals results in the release of immunosuppression and promotes anti-tumor T cell reactivity.

Unpublished data from our research group, emerging in collaboration with the biotech company InProTher suggests a novel immune checkpoint receptor-ligand pair consisting of an adhesion G protein-coupled receptor (GPCR) and a viral protein.

With therapeutic targeting of GPCRs being our main focus, we - together with our collaboration partner InProTher - aim to investigate the blockade of the interaction between immune cells expressing the adhesion GPCR and cancer cells expressing the viral protein as novel ICI and cancer therapy strategy. The exploration of novel immune checkpoints and expanding the repertoire of cancer therapy drugs are paramount for overcoming therapeutic resistance and advancing cancer treatment.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

KOBENHAVNS UNIVERSITET
Net EU contribution
€ 150 000,00
Address
NORREGADE 10
1165 KOBENHAVN
Denmark
Region
Danmark Hovedstaden Byen København
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)